Lymphomas and Chronic Lymphocytic Leukemia

Expert faculty review and share their insights and perspectives on key findings in lymphomas and chronic lymphocytic leukemia presented at the 2020 ASH Annual Meeting.

Share

Program Content

Activities

  • Expert Analysis
    Key Studies in Lymphomas: CCO Independent Conference Highlights of the 2020 Virtual ASH Annual Meeting
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: February 26, 2021

    Expires: February 25, 2022

  • ClinicalThought
    Expert Selections From ASH 2020: Lymphomas/CLL
    Clinical Thought
    Conference Coverage
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 11, 2021

    Expires: March 10, 2022

  • Podcast
    Expert Insights on Highlights From ASH 2020 on Lymphomas/CLL
    Conference Coverage
    Podcast Episodes
    Congratulations: You achieved a completion on 04/09/2022

    Released: March 26, 2021

    Expires: March 25, 2022

Activities

Liso-cel in R/R MCL
TRANSCEND NHL 001: R/R MCL Cohort of Phase I Study of Lisocabtagene Maraleucel
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

Ibrut + Ven for CLL
CAPTIVATE: Updated Results From the Phase II Trial of First-line Ibrutinib Plus Venetoclax for CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

VenR for R/R CLL: 5-Yr FU
MURANO 5-Yr Analysis: Fixed-Duration Venetoclax + Rituximab vs Bendamustine + Rituximab in R/R CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

Phase Ib ACE-CL-003 Trial
Phase Ib ACE-CL-003: Acalabrutinib Combined With Venetoclax and Obinutuzumab or Rituximab in Treatment-Naive or Relapsed/Refractory CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Tazemetostat in R/R FL
Predictors of Response to Third-Line Tazemetostat in Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 11, 2020

Expires: December 10, 2021

Umbralisib for R/R iNHL
UNITY-NHL: Umbralisib Monotherapy in Patients With R/R Indolent NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Acala in CLL: CV Events
Pooled Analysis of Cardiovascular Events From Clinical Trials Evaluating Acalabrutinib Monotherapy in CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

Parsaclisib in R/R MZL
CITADEL-204 Phase II Trial of Parsaclisib, a PI3Kδ Inhibitor, in Relapsed/Refractory Marginal Zone Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 08, 2020

Expires: December 07, 2021

Odronextamab in B-NHL
Phase I Study of Odronextamab, a Novel Bispecific Antibody Targeting CD3 and CD20, for Patients With Heavily Pretreated B-Cell NHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 10, 2020

Expires: December 09, 2021

cHL: Initial BV for Older Pts
SGN35-015: Phase II Study of Frontline Brentuximab Vedotin ± Second Agent for Older Patients With cHL Ineligible for Standard CT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2020

Expires: December 13, 2021

Phase I/II BRUIN Trial
Phase I/II BRUIN Trial of LOXO-305 in Previously Treated Patients With CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2020

Expires: December 16, 2021

CLL: Umbralisib/Ublituximab
UNITY-CLL: Phase III Trial of Umbralisib + Ublituximab vs Obinutuzumab + Chlorambucil in Patients With CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Liso-cel/Ibrut in CLL/SLL
TRANSCEND CLL 004: Phase I Results With Lisocabtagene Maraleucel + Ibrutinib in Relapsed/Refractory CLL/SLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 09, 2020

Expires: December 08, 2021

ZUMA-5
ZUMA-5: Phase II Study of Axicabtagene Ciloleucel in R/R Indolent Non-Hodgkin Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2020

Expires: December 17, 2021

Mosunetuzumab in R/R FL
Phase I Trial of Mosunetuzumab Bispecific Antibody in Multiply Relapsed Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2020

Expires: December 14, 2021

Faculty

cover img faculity

Jeremy S Abramson, MD, MMSc

Director, Center for Lymphoma
Mass General Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Provided by

ProCE Banner

Supporters

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology